FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Advisors to Consider Peanut Allergy Treatment

FDA asks the Allergenic Products Advisory Committee to comment on whether efficacy and safety data support approval of Aimmune Therapeutics Palforzia ...

Federal Register

Calcimar Not Withdraw Due to Safety/Efficacy

Federal Register notice: FDA determines that Sanofi Aventis Calcimar (calcitonin salmon) injection, 200 IU/mL was not withdrawn from sale due to safet...

Federal Register

Aegea Vapor System Regulatory Review Period

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Tsunami MedTechs Aegea Vapor System, indicated ...

Human Drugs

Suggestions for Use Instructions Guidance

Four stakeholders suggest changes to an FDA draft guidance on the format and content of instructions for use information for drugs, biologics, and com...

Federal Register

Comments Sought on 21 Substances for Drug Scheduling

Federal Register notice: FDA requests comments on 21 drug substances concerning abuse potential, actual abuse, medical usefulness, trafficking, and im...

Human Drugs

Crysvita BLA to be Submitted

Ultragenyx and Kyowa Kirin say they will submit an sBLA for a new indication for their Crysvita in the first half of 2020.

Human Drugs

Courts Let Companies Keep Drug Risks Secret: Reuters

A Reuters investigative report examines the way in which a federal court allowed Merck to keep some Propecia risk information secret during considerat...

Human Drugs

Hospira Recalls 1 Lot of Bacteriostatic Water

Hospira recalls one lot of its bacteriostatic water for injection, USP, 30 mL, multi-dose vial due to sterilization concerns.

Human Drugs

FDA Aims to Ban Flavored e-Cigarettes

FDA moves to ban non-tobacco-flavored e-cigarettes at the urging of President Trump during a 9/11 White House meeting with acting commissioner Ned Sha...

Human Drugs

Nerlynx sNDA for 3rd-line HER2 Breast Cancer

FDA accepts for review a Puma Biotechnology supplemental NDA for Nerlynx (neratinib) in combination with capecitabine for treating patients with HER2-...